UnmeshShah Ph.D.


New York + 1.212.326.8324

Unmesh Shah assists in the drafting and prosecution of U.S. and foreign patent applications as well as with due diligence and patentability analyses projects for pharmaceutical/biotechnology clients.

Prior to joining Jones Day, Unmesh worked as a medicinal chemist at Schering-Plough and Merck for 14 years. During his tenure in the pharmaceutical industry, he designed, synthesized, and advanced several drug candidates to clinical trials. Unmesh's experience in life science research covers several therapeutic areas, including infectious, central nervous system, cardiovascular, and metabolic disorders.

Unmesh conducted his doctoral research in the field of total synthesis of natural products. As part of his Ph.D. research, he successfully completed the first total synthesis of a complex alkaloid, himgaline and published this work in the Journal of the American Chemical Society. Unmesh has been a peer reviewer of scientific articles and is a lead author on a number of scientific publications, including invited review articles and book chapters. He is an inventor of approximately 12 granted U.S. patents and 19 published PCT applications. Additionally, Unmesh has given several oral and poster presentations at national meetings. He is a member of the American Chemical Society.


  • Puma Biotechnology asserts patent infringement claims under Hatch-Waxman Act related to Nerlynx® against SandozJones Day is representing Puma Biotechnology, Inc. in a Hatch-Waxman patent infringement action against Sandoz relating to Sandoz's submission of an Abbreviated New Drug Application to the FDA seeking approval of a purported generic version of Nerlynx® (neratinib) tablets.
  • Merck asserts patent infringement claims under Hatch-Waxman Act relating to Bridion® against 16 generic drug makersJones Day is representing Merck & Co., Inc. in Hatch-Waxman patent infringement actions against 16 generic drug maker defendant groups, relating to the defendant groups' submissions of Abbreviated New Drug Applications to the FDA seeking approval of generic versions of Bridion®, a first-in-class agent for the reversal of certain types of neuromuscular blockade in adults undergoing surgery.